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Abstract
Background: Improved tests to diagnose latent TB infection (LTBI) are needed. We sought to evaluate the
performance of two commercially available interferon-gamma release assays (IGRAs) compared to the tuberculin
skin test (TST) for the diagnosis of LTBI and to identify risk factors for LTBI among HIV-infected individuals in Georgia,
a country with high rates of TB.
Methods: HIV-patients were enrolled from the National AIDS Center in Tbilisi, Georgia. After providing informed
consent, each participant completed a questionnaire, had blood drawn for QuantiFERON-TB Gold in-Tube (QFT-GIT) and
T-SPOT.TB testing and had a TST placed. The TST was read at 48–72 hrs with ≥ 5 mm induration considered positive.
Results: Between 2009–2011, 240 HIV-infected persons (66% male) with a median age of 38 years and a median CD4
count of 255 cells/μl (IQR: 124–412) had diagnostic testing for LTBI performed. 94% had visible evidence of a BCG scar.
The TST was positive in 41 (17%) patients; QFT-GIT in 70 (29%); and T-SPOT.TB in 56 (24%). At least one diagnostic test
was positive in 109 (45%) patients and only among 13 (5%) patients were all three tests positive. Three (1%) QFT-GIT and
19 (8%) T-SPOT.TB test results were indeterminate. The agreement among all pairs of tests was poor: QFT-GIT vs. T-SPOT.
TB (κ = 0.18, 95% CI .07-.30), QFT-GIT vs. TST (κ = 0.29, 95% CI .16-.42), and TST vs. T-SPOT.TB (κ = 0.22, 95% CI .07-.29). Risk
factors for LTBI varied by diagnostic test and none showed associations between positive test results and well-known risk
factors for TB, such as imprisonment, drug abuse and immunological status.
Conclusions: A high proportion of HIV patients had at least one positive diagnostic test for LTBI; however, there was
very poor agreement among all tests. This lack of agreement makes it difficult to know which test is superior and
most appropriate for LTBI testing among HIV-infected patients. While further follow-up studies will help determine the
predictive ability of different LTBI tests, improved modalities are needed for accurate detection of LTBI and assessment
of risk of developing active TB among HIV-infected patients.
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Background
HIV is the greatest risk factor for progression of recent or
latent tuberculosis infection (LTBI) to active tuberculosis
(TB) disease. The risk of developing active TB is more
than 20 times greater in HIV patients as compared to im-
munocompetent persons [1,2]. Given this extremely high
risk, the accurate diagnosis and subsequent treatment of
LTBI among persons living with HIV (PLHIV) is regarded
as an essential component of TB control strategy [3,4].
Yet, the best available diagnostic tools for LTBI are not
fully defined.
T-cell based interferon-gamma release assays (IGRA)
offer several advantages over the tuberculin skin test
(TST), including better specificity (especially among those
with Bacille Calmette-Guérin [BCG] vaccination), elimin-
ation of the subjectivity of TST reading, and logistic con-
venience [5,6]. However, the data comparing IGRAs and
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the TST in immunocompromised persons is limited and
shows no clear superiority of one test over another [7].
Following the collapse of Soviet Union, the country of
Georgia experienced significant socio-economic upheavals
resulting in a deterioration of public health infrastructure
and resurgence of TB in the 1990s. TB incidence rates in-
creased from 28/100,000 to 186/100,000 between 1990
and 1997 and continue to remain high at 125 TB cases
per 100,000 population in 2011 [8]. While Georgia has
been able to avoid a large-scale HIV epidemic, 3,642 HIV
cases have been reported since 1989. The estimated adult
HIV prevalence in Georgia is 0.2%, [9] but the number of
reported HIV cases has been steadily increasing. Similar
to other Eastern European countries the HIV epidemic in
Georgia has been driven by injection drug use (IDU) ac-
counting for 54% of total reported cases. HIV, substance
abuse, incarceration and low socioeconomic status are
well-known risk factors for TB, [10-12] which may con-
tribute to the significant impact of TB among PLHIV in
Georgia. Data from the national HIV/AIDS clinical pro-
gram found that 20% of registered HIV patients had re-
ceived a diagnosis of TB, and that TB was responsible for
25% of all deaths among PLHIV in the country [13].
Addressing the TB/HIV co infection has become a
country health priority and a national TB/HIV strategic
plan was developed in 2007. While there is well estab-
lished collaborative network ensuring free access to both
TB and HIV medical care in Georgia the diagnosis and
treatment of LTBI among PLHIV needs to be scaled-up.
The objectives of the present study were to assess the
performance of two commercially available IGRAs
(QuantiFERON-TB Gold in Tube [QFT-GIT] and T-
SPOT.TB [TSPOT]) compared to the TST for the diag-
nosis of LTBI in HIV-infected patients, and to identify
risk factors for LTBI in effort to improve the TB preven-
tion and care among PLHIV in Georgia.
Methods
Study setting and population
A cross-sectional study was conducted at the Infectious
Diseases, AIDS and Clinical Immunology Research Center
(IDACIRC) in Tbilisi, Georgia between November 2009
and June 2011. The IDACIRC is the national referral insti-
tution for HIV diagnosis, treatment and care. Inclusion cri-
teria for study enrollment included age ≥18 years old,
confirmed HIV infection, and ability to provide written
informed consent. Patients with a history of active TB
disease were excluded. After informed consent, all
participants completed a study questionnaire, and
were tested for LTBI using the IGRAs and TST. Blood
was drawn for the IGRAs prior to the placement of
the TST.
All patients were interviewed to collect information re-
garding socio-demographic characteristics, history of BCG
vaccination, imprisonment, tobacco use and substance
abuse. Patients were screened for illicit drug use and alco-
hol abuse using the Drug Abuse Screening Test (DAST-
10) [14] and the Alcohol Use Disorders Identification Test
(AUDIT) [15] respectively. Additionally, medical chart ab-
straction was performed to collect the following informa-
tion: most recent CD4+ T-cell count, HIV-1 viral load,
hepatitis B virus (HBV) and hepatitis C virus (HCV) sta-
tus, and antiretroviral therapy (ART) use.
The study was approved by the IDACIRC and Emory
University institutional review boards (IRBs).
TST and IGRA assays
The TST was performed using the Mantoux method. An
intradermal injection of 0.1 ml purified protein derivative
was administered into the volar surface of the forearm.
The transverse diameter of induration was recorded in
millimeters 48–72 hours after administration. An indur-
ation of ≥ 5 mm of induration was considered positive
among the HIV-infected persons included in this study
[16]. Each participant had approximately 12 ml of blood
drawn for the QFT-GIT and TSPOT, which were per-
formed according to the manufacturer’s instructions. Both
the QFT-GIT and TSPOT were performed at the IDA-
CIRC laboratory.
As recommended by the manufacturer and the U.S.
Centers for Disease Control and Prevention (CDC), [17]
the QFT-GIT result was considered positive if the
interferon-gamma response to TB antigens minus the
negative control was ≥ 0.35 IU/ml and also > 25% of the
negative control; negative if these criteria were not met;
and indeterminate if either the negative control had a
result of > 8 IU/ml or the positive control had a result
of < 0.5 IU/ml. For TSPOT 250,000 peripheral blood
mononuclear cells (PBMCs) were isolated and plated per
well: a nil control, a positive control containing phyto-
hemagglutinin and TB specific antigens (CFP-10 and
ESAT-6). Spot forming units were counted using AID Eli-
Spot Reader System (Autoimmun Diagnostika, Germany).
The test result was considered reactive if the response to
either CFP-10 or ESAT-6 minus the nil control was ≥ 6
spot forming cells, or twice the nil control. The result was
considered indeterminate if nil control spot count was >
10 spot forming cells or if the reading in the positive con-
trol was < 20 spot forming cells.
Statistical analysis
Study data were collected and managed using REDCap
electronic data capture tools hosted at Emory University
[18]. All statistical analyses were performed using SAS 9.2
(SAS Institute, Cary, NC USA). Distributions of outcome
variables and covariates were evaluated in descriptive sta-
tistics. The impact of immunosuppression as measured by
the CD4+ T-cell count (<100, 100–200, >200 cells/uL) on
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LTBI test results was studied using a stratified analysis.
Agreement between the three LTBI tests was evalu-
ated using kappa (k) statistic, where κ > 0.75 represents
excellent agreement, κ = 0.4-0.75 represents fair to good
agreement, and κ <0.4 represents poor agreement [19].
Univariate logistic regression analysis was performed to
identify risk factors associated with a positive LTBI test re-
sult. A purposeful variable selection strategy was used to
build the final multivariate logistic regression models [20].
Criterion for retaining variables in the model was set at p
value of 0.10. Confounding was assessed as 20% change in




A total of 240 HIV-infected patients were enrolled in the
study (Table 1). The median age was 38 years (range 33 –
44) and 66% were male. Nearly one in five (19%) patients
had a history of imprisonment and 46% were co-infected
with hepatitis C virus (HCV). The median CD4+ T-cell
count of study participants was 255 cells/μl and 62 (26%)
were receiving antiretroviral therapy (ART) for a median
duration of 3 months. Visible evidence of BCG scar was
present in 94% of patients. With regard to substance use,
63% of patients were current tobacco users, 13% had
medium to high level of alcohol consumption as mea-
sured by the AUDIT screen, and 33% reported a medium
to severe level of drug abuse by DAST screen.
LTBI test results
Among the 240 study participants, 109 (45%) had at least
one positive test result. The prevalence of a positive TST
was 17%, QFT-GIT 29%, and TSPOT 24% (Table 2). There
were significantly more indeterminate TSPOT test results
as compared to the QFT-GIT and TST (8% vs. 1% vs. 1%,
P < 0.05). There were more positive test results using the
IGRAs compared to the TST among patients with CD4
count <200 cells/μl, with difference between TSPOT and
TST reaching statistical significance (TSPOT 29% vs. TST
16%, p = 0.01 and QFT-GIT 25% vs. TST 16%, p = 0.10).
Overall,There were also more positive QFT-GIT and
TSPOT test results as compared to the TST among pa-
tients with CD4 counts < 100 cells/μl, but the differences
did not reach statistical significance (26% vs. 26% vs. 13%,
respectively, p = 0.12).
Table 1 Patient characteristics of HIV-infected subjects
undergoing latent tuberculosis testing (n = 240)
Characteristic All subjects n (%)
Male 159 (66%)
Age, median (IQR) 38.0 (32.8-43.8)
High school education or less 124 (52%)
Unemployed 172 (72%)
Married 116 (48%)
History of imprisonment 46 (19%)
Household members, median (IQR) 3.0 (3.0-4.0)
HIV related factors
On ART, at enrollment
median time on ART (months)
62 (26%)
3
CD4 Count, median (IQR) 255 (124–412)
HIV RNA < 75 copies/ml 28 (12%)
Hepatitis C antibody positive 111 (46%)
Hepatitis B surface antigen positive 9 (4%)
TB related factors
Household member with prior TB treatment 13 (5%)
Self reported BCG vaccination 173 (72%)
BCG scar 219 (94%)
Drug use
Current tobacco smokers 152 (63%)
Alcohol abuse measure (per AUDIT score)










Table 2 Overall TST, QFT-GIT, and T.SPOT results and per
CD4 category
Test results CD4 count categories Overall
n = 240 (%)<100
n = 54 (%)
100-200
n = 37 (%)
>200
n = 149 (%)
TST results
TST + 7 (13) 8 (22) 26 (18) 41 (17)
TST - 47 (87) 29 (78) 121 (82) 197 (83)
Indeterminate* 0 0 2 (1) 2 (1)
QFT-GIT results
QFT + 14 (26) 9 (24) 47 (31) 70 (29)
QFT - 38 (70) 28 (76) 101 (68) 167 (70)
Indeterminate 2 (4) - 1 (1) 3 (1)
T.SPOT results
T.SPOT + 14 (26) 12 (32) 30 (20) 56 (24)
T.SPOT - 34 (64) 20 (54) 108 (73) 162 (68)
Indeterminate 5 (10) 5 (14) 10 (7) 20 (8)
* Either patient did not come to have read or returned > 72 hours after
TST placement.
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The overall concordance among the tests was poor;
all three test results were in agreement only 54% of the
time (129/240) (Figure 1). Only 13 (5%) patients had a
positive result for all three LTBI diagnostic tests (TST,
QFT-GIT, and TSPOT) and 116 (48%) patients had a
negative test result for all three diagnostic tests. Two
TST results were invalid and two IGRA results were
missing. As measured by the Kappa statistic and shown
in Table 3 the agreement between any two LTBI tests
was poor: QFT-GIT vs. TSPOT k = 0.18 (95% CI: 0.07-
0.30), QFT-GIT vs. TST k = 0.29 (95% CI: 0.16-0.42), TST
vs. TSPOT k = 0.22 (95% CI: 0.07-0.29).
In comparing quantitative QFT-GIT results stratified by
TST and TSPOT test results, we found higher median and
mean QFT-GIT results in patients with a positive TST as
compared to a negative TST (Table 4). There was no sig-
nificant difference of mean and median QFT-GIT results
between TSPOT positive and negative patients. Regardless
of the TST result, the mean QFT-GIT response was lower
among patients with indeterminate TSPOT results com-
pared to either positive or negative TSPOT results.
Risk factors for positive LTBI test
The results of univariate and multivariate logistic regres-
sion analyses evaluating risk factors for a positive LTBI
test result are shown in Table 5. Risk factors were
assessed separately for each diagnostic test. None of the
well-known risk factors for TB, such as imprisonment,
drug abuse and immunological status were associated
with positive test results. In multivariate analysis HCV
co-infection (aOR 2.18, 95% CI 1.01-4.71) and receiving
ART (aOR 0.15, 95% CI 0.04-0.52) were significantly as-
sociated with a positive TST result. Male gender was the
only risk factor significantly associated with a positive
QFT test (aOR 2.92. 95% CI 1.49-5.74). Increasing age
per year (aOR 1.04, 95% CI 1.002-1.08) and chronic
hepatitis B infection (aOR 5.13, 95% CI 1.24-21.17) were
the only factors significantly associated with a positive
T-SPOT.TB test in multivariate analysis.
Discussion
We found that a high proportion of HIV-infected pa-
tients in the country of Georgia had at least one positive
LTBI test result (45%) with either the TST, QFT-GIT,
or TSPOT assay. The higher proportion of positive
IGRA test results as compared to the TST was most
pronounced among patients with CD4 counts ≤ 100 μl,
suggesting the IGRAs may perform better in highly im-
munocompromised patients. However, the lack of a gold
standard for the diagnosis of LTBI, scarcity of data re-
garding the long term predictive value of IGRAs, and
the very poor agreement among the three tests makes it
unclear which test is optimal. While it is unclear which
240 received QFT-GIT, T.SPOT, and TST
195 TST negative*
116 QFT-GIT- / T.SPOT-
22 QFT-GIT- / T.SPOT+
10 QFT-GIT- / T.SPOT ID
26 QFT-GIT+/ T.SPOT-
12 QFT-GIT+ / T.SPOT+
6 QFT-GIT+ / T.SPOT ID
3 QFT-GIT ID/ (1 T.SPOT - / 2 T.SPOT+)
41 TST+
13 QFT-GIT+ / T.SPOT+
10 QFT-GIT+ / T.SPOT-
2 QFT-GIT+ / T.SPOT ID
8 QFT-GIT- / T.SPOT-
7 QFT-GIT- / T.SPOT+
1 QFT-GIT- / T.SPOT ID
2 TST invalid
Figure 1 Flow diagram for HIV-infected persons who underwent QFT-GIT, T.SPOT and TST. *2 QFT-GIT and T.SPOT results missing.
Shaded cells indicate agreement between all three tests. ID = indeterminate.
Table 3 Agreement between TST, QFT-GIT and T-SPOT.TB
Kappa (95% CI)
QFT-GIT vs. TSPOT 0.18 (95% CI: 0.07-0.30)
QFT-GIT vs. TST 0.29 (95% CI: 0.16-0.42)
TST vs. TSPOT 0.22 (95% CI: 0.07-0.29)
Table 4 Median and average QFT-GIT test result values



















1.33 0.64-1.87 2 QFT-GIT +/
T.SPOT ID
1.55 0.56-2.54
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LTBI test performed best, our study does demonstrate
that LTBI is common among HIV infected patients in
Georgia and is an urgent problem that needs addressing.
The diagnosis and treatment of LTBI is a key compo-
nent of the WHO three I’s program for decreasing the
impact of TB among HIV-infected persons [3,4]. Accur-
ate identification of patients with LTBI remains chal-
lenging. In the absence of gold standard, agreement
between tests serves as surrogate marker for perform-
ance. Our study showed poor agreement both between
IGRAs and TST, and between the two IGRAs. Agree-
ment was especially low between QFT-GIT and TSPOT
(k = 0.18), which is similar to other reports [21-23].
Some studies have reported better agreement, but never
surpassing moderate levels [24,25]. The reason for dis-
cordance between the two IGRAs in our patient popula-
tion is unclear. Additionally, we found no difference in
quantitative QFT-GIT values based on TSPOT results fur-
ther confirming the discordance between the two tests.
Indeterminate results were more common with T.SPOT
(8%) compared to QFT (1%). In our study, indeterminate
results did not seem to be associated with degree of im-
munodeficiency as seen elsewhere [22,26,27]. Given the
poor concordance between diagnostic tests, our study
suggests the urgent need for new and better diagnostic
tests for LTBI, especially among HIV-infected persons
who are at greatest risk for progression to active TB di-
sease following infection.
The proportion of patients with positive test results
among those with severe immunodeficiency (CD4
count <100 cells/μl) was higher with IGRAs as com-
pared to the TST (26% vs. 13%, p = 0.12) but the differ-
ences were not statistically significant. The TSPOT and
QFT-GIT also yielded higher proportions of positive test
results that the TST among patients with CD4 count <200
cells/μl (TSPOT 29% vs. TST 16%, p = 0.01 and QFT-GIT
25% vs. TST 16%, p = 0.10). Additionally, in contrast to
prior studies, reporting significantly lower proportion
of positive IGRA test results in patients with CD4
count <200cell/μl, in our study both the QFT-GIT and
TSPOT had similar proportions of positive test results for
patients above and below a CD4 count of 200 cells/μl [7].
Some authors have suggested, [25,28] that the IGRAs are
more sensitive for detection infection with M. tuberculosis
in immunosuppressed patients than TST. However, ab-
sence of gold standard makes it difficult to conclude
whether IGRAs outperformed TST, or if there is a higher
rate of false positive results. One recent study found a
high rate of positive QFT-GIT tests that reverted to nega-
tive upon repeat testing in low risk HIV-infected patients
[29]. The reversion rate was much higher in American
born HIV-infected patients (80%) as compared to pa-
tients originally from high incidence TB countries
(25%), such as Georgia.
Multivariate analysis of risk factors for LTBI showed
heterogeneity across diagnostic tests. Positive TST was
Table 5 Logistic regression analysis of association of risk factors for LTBI with a positive TST, QFT-GIT, and
T-SPOT.TB result
Risk factors Positive TST result Positive QFT-GIT Positive T-SPOT.TB
n = 41 n = 70 n = 56
Univariate Multivariate Univariate Multivariate Univariate Multivariate
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR p OR 95% CI
Male 1.75 0.81-3.77 2.92 1.49-5.75 2.92 1.49-5.75 1.93 0.97-3.84 1.82 0.90-3.67
Age (per year) 1.01 0.97-1.05 1.01 0.97-1.04 1.04 1.004-1.08 1.04 1.003-1.08
Imprisonment 2.31 1.08-4.92 2.09 0.88-4.97 2.22 1.14-4.31 1.78 0.88-3.61
Unemployment 0.80 0.38-1.69 1.22 0.63-2.34 1.15 0.57-2.33
On ART 0.19 0.06-0.62 0.15 0.04-0.52 0.80 0.42-1.53 0.66 0.32-1.39
VL <75 0.34 0.08-1.48 0.63 0.24-1.63 1.10 0.44-2.73
CD4 <100 - - - - - -
100 < CD4 <200 1.85 0.61-5.65 0.92 0.35-2.42 1.34 0.53-3.36
CD4 >200 1.44 0.59-3.55 1.32 0.66-2.65 0.71 0.34-1.47
Hepatitis C Ab + 2.38 1.19-4.77 2.18 1.01-4.71 1.72 0.98-3.00 1.78 0.97-3.26
Hepatitis B sAG + 1.39 0.28-6.96 2.00 0.52-7.68 4.36 1.13-16.85 5.13 1.24-21.17
Household Member treated for TB 1.48 0.39-5.62 0.43 0.09-1.97 1.48 0.44-5.00
BCG 2.55 0.32-20.18 1.41 0.38-5.29 1.78 0.38-8.28
Tobacco 1.32 0.65-2.71 2.02 1.09-3.75 1.16 0.62-2.18
ETOH (AUDIT > = 8) 1.42 0.57-3.54 0.94 0.41-2.16 1.87 0.84-4.17
Drug Use (DART > =3) 2.02 1.02-4.01 2.33 1.31-4.16 1.42 0.76-2.64
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associated with co-infection with hepatitis C and being
on ART (protective effect), male gender was associated
with positive QFT-GIT test, and increasing age together
with chronic hepatitis B infection were significantly as-
sociated with positive TSPOT result. Well known risk
factors for tuberculosis, such as imprisonment and drug
abuse, [30] were associated with the outcome only in
univariate analysis, but not in multivariate. Association
of viral hepatitis co-infection with TST and TSPOT posi-
tivity merits further exploration.
This study has several limitations. Although our study
sample size is comparable to previous reports, we had a
relatively small number of HIV-infected patients with
low CD4 counts. Our study was cross sectional so there
was no patient follow up for the development of active
tuberculosis. This prohibited us from evaluating the pre-
dictive value of IGRAs for the development of active tu-
berculosis among HIV-infected patients. Further studies
are needed to assess the predictive value of IGRAs for
active TB, especially among immunocompromised pa-
tients such as those with HIV infection [31-33].
There remains uncertainty about which is the best
diagnostic test for LTBI among HIV-infected persons.
Despite the uncertainty, a growing number of guidelines
support the use of IGRA for the diagnosis of LTBI (ei-
ther in combination with TST or alone) [34]. In addition,
recent ART guidelines from the WHO Regional Office
for Europe identifies IGRAs as preferred diagnostic
method for LTBI screening in HIV patients WHO does
not support the use of IGRAs in low and middle income
countries, [35] Given the poor concordance among the
three diagnostic tests (and between the two commer-
cially available IGRAs), our data supports the WHO rec-
ommendations regarding the use of these diagnostic
tests in low and middle income countries. Recent U.S.
CDC guidelines recommend use IGRAs in persons with
BCG vaccination and those with low rates of returning
to have TST read [17]. The CDC and Canadian Tuber-
culosis Committee (CTC) guidelines also discuss the
possible utility of dual testing with IGRAs and TST for
LTBI among high-risk individuals [17,36]. The CTC spe-
cifically recommends performing an IGRA in immuno-
compromised individuals with a strong suspicion for
LTBI if the initial TST is negative. If this strategy was
used for our patient cohort an additional 44 patients and
36 patients would have been diagnosed with LTBI by the
QFT-GIT and TSPOT tests respectively. Given the vary-
ing performance and agreements of LTBI tests across
different settings it is likely that different strategies will
be needed depending on the population. Additional fac-
tors that need to be taken into consideration included
patients preferences, logistics, and test cost. The cost of
a single IGRA may be up to three times as a high as the
cost of a TST [37,38].
Conclusion
In summary, we report the first study to evaluate per-
formance of three diagnostic tests for LTBI in HIV pa-
tients in the Eastern European region. While our study
showed a high prevalence of LTBI we also found a poor
concordance between all LTBI diagnostic tests (QFT-
GIT, TSPOT, and TST) including between the two
different commercially available IGRAs. Multivariate
analysis did not identify one specific population sub-
group at higher risk of LTBI. Variation in risk factors for
LTBI across the tests reflects poor agreement between
available diagnostic modalities. This lack of agreement
makes it difficult to identify most appropriate test for
LTBI diagnosis among HIV-infected patients. Without
clear evidence of superiority of IGRAs, choosing test for
LTBI, particularly in resource-limited settings, should ac-
count for costs and logistics. While long-term follow-up
studies will help to better understand the role of IGRAs
among HIV infected patients, improved modalities are
needed to accurately identify HIV-infected patient at
highest risk of developing active TB, who will benefit the
most from LTBI treatment.
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